Dier Mardi
EVP and CFO
Dier Mardi has filed 3 SEC Form 4 filings (30 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Mar 6, 2026.
On the most recent filing, Dier Mardi is listed as EVP and CFO at MADRIGAL PHARMACEUTICALS, INC. Inside the rolling window, Dier Mardi reported no open-market purchases and 3 open-market sales totaling $3.8M in MDGL. The largest disclosed transaction in the window is a sale of 4,173 MDGL shares on Dec 2, 2025, worth $2.4M.
Companies traded
Other insiders at MDGL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.8M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Dier Mardi made?
Dier Mardi has filed 3 SEC Form 4 filings (30 transaction rows) across 1 company since 2025.
Which companies does Dier Mardi trade?
Dier Mardi has filed SEC Form 4 disclosures for 1 company, including MDGL.
When was Dier Mardi's most recent SEC Form 4 filing?
Dier Mardi's most recent SEC Form 4 filing on Tracefour is dated Mar 6, 2026.
What is Dier Mardi's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Dier Mardi is listed as EVP and CFO.
What is Dier Mardi's total buy and sell value in the current window?
Inside the rolling retention window, Dier Mardi bought $0 and sold $3.8M based on SEC Form 4 filings.
What was Dier Mardi's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 4,173 MDGL shares on 2025-12-02, worth $2.4M, per SEC Form 4 filings.